Here are the 10-K annual reports from Immunocore Holdings plc (IMCR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow IMCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMCR filings page.
Immunocore Holdings plc is a commercial-stage biotech company built on its ImmTAX bispecific TCR platform, aiming to treat cancer, infectious and autoimmune diseases. Its first product, KIMMTRAK, is approved for metastatic uveal melanoma in 39 countries and launched commercially in 30.
In 2025, revenue from sale of therapies reached $400.0 million, up from $310.0 million in 2024, driven mainly by the United States at $257.0 million, with Europe contributing $131.4 million and international markets $11.6 million. As of January 31, 2026, Immunocore had 50,695,078 ordinary shares outstanding.
The company is running multiple late-stage oncology trials, including three Phase 3 studies for KIMMTRAK and PRAME‑targeted brenetafusp, and advancing infectious disease candidates for HIV and hepatitis B as well as new autoimmune programs IMC‑S118AI and IMC‑U120AI. Management highlights ongoing losses, funding needs, competitive pressures, regulatory risk and IP challenges as key risk factors.